Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242 [PMID: 26600982 DOI: 10.4291/wjgp.v6.i4.235]
Corresponding Author of This Article
Steven A White, Professor, HPB and Transplant Consultant, HPB Unit, Freeman Hospital, Freeman Road, Newcastle upon Tyne, Tyne and Wear NE7 7DN, United Kingdom. steven.white@nuth.nhs.uk
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 235-242 Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.235
Table 1 Differences in Kaplan-Meier estimated median survival between individual drugs groups
Drug name
Number taking the drug out of 164 patients
Median survival estimate for those taking the drug (d)
Median survival for those not taking the drug (d)
P value (log rank test)
ACEI/ARB
41
539
611
0.652
CCB
26
815
528
0.061
Aspirin
55
504
546
0.846
Statins
39
504
577
0.368
Table 2 Univariate and multivariate cox regression comparing individual drug groups with those not taking the drug
Drug name
Number taking the drug out of 164 patients
Univariate analysis
Multivariate analysis
HR (95%CI)
P-value
HR (95%CI)
P-value
ACEI/ARB
41
1.094 (0.741-1.614)
0.653
1.129 (0.617-2.065)
0.693
CCB
26
0.635 (0.393-1.025)
0.063
0.475 (0.250-0.902)
0.023
Aspirin
55
1.036 (0.726-1.479)
0.846
1.041 (0.651-1.667)
0.865
Statins
39
1.200 (0.806-1.787)
0.369
1.055 (0.614-1.814)
0.845
Table 3 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of medications with patients on one or neither drug
Drug combination
Number of people on
Kaplan-Meier estimated median survival
Multivariate cox regression
combination out of 164
For those on the drug combination
For those not on drug combination
P-value (log rank)
HR (95%CI)
P-value
CCB + aspirin
15
1414
528
0.012
0.300 (0.122-0.735)
0.008
CCB + statin
12
544
539
0.284
0.413 (0.155-1.101)
0.077
CCB + ACEI/ARB
12
485
541
0.450
0.512 (0.194-1.348)
0.175
Aspirin + statin
27
504
546
0.697
0.969 (0.509-1.844)
0.924
Aspirin + ACEI/ARB
22
485
569
0.923
0.948 (0.438-2.054)
0.893
Statin + ACEI/ARB
21
368
577
0.426
1.126 (0.533-2.379)
0.756
Table 4 Comparison of differences in prognostic indicators between drug groups
Characteristics
No CCB/aspirin, n (%)
CCB and aspirin, n (%)
Aspirin without CCB, n (%)
CCB without Aspirin, n (%)
P value
n = 98
n = 15
n = 40
n = 11
Sex
Male
56 (57.1)
5 (33.3)
25 (62.5)
8 (72.7)
0.169
Age (yr)
< 60
39 (39.8)
5 (33.3)
8 (20.0)
3 (27.3)
0.157
≥ 60
59 (60.2)
10 (66.7)
32 (80.0)
8 (72.7)
Blood pressure status
Hypertensive
27 (27.6)
13 (86.7)
22 (55.0)
11 (100.0)
0.000
Non-hypertensive
71 (72.4)
2 (13.3)
18 (45.0)
0 (0.0)
BMI
< 18.5
2 (2.0)
0 (0)
1 (2.5)
0 (0.0)
0.307
18.5-25
52 (53.1)
5 (33.3)
24 (60.0)
3 (27.3)
> 25
41 (41.8)
9 (60.0)
14 (35.0)
8 (72.7)
Adjuvant chemotherapy
Received post-op
69 (70.4)
9 (60.0)
23 (57.5)
9 (81.8)
0.333
Not received
24 (24.5)
5 (33.3)
13 (32.5)
1 (9.1)
CA19-9
< 47
27 (27.6)
3 (20.0)
9 (22.5)
1 (9.1)
0.437
47-1000
51 (52.0)
7 (46.7)
20 (50.0)
7 (63.6)
> 1000
8 (8.2)
3 (20.0)
6 (15.0)
3 (27.3)
ASA grade
1-2
81 (82.7)
12 (80.0)
22 (55.0)
8 (72.7)
0.008
3-4
17 (17.3)
3 (20.0)
18 (45.0)
3 (27.3)
Resection value
R0
14 (14.3)
6 (40.0)
9 (22.5)
5 (45.5)
0.020
R1
83 (84.7)
9 (60.0)
31 (77.5)
6 (54.5)
T status
T1-2
3 (3.1)
2 (13.3)
1 (2.5)
0 (0.0)
0.199
T3-4
95 (96.9)
13 (86.7)
39 (97.5)
11 (100.0)
N status
N0
7 (7.1)
3 (20.0)
5 (12.5)
0 (0.0)
0.242
N1
90 (91.8)
12 (80)
35 (87.5)
11 (100.0)
Table 5 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of calcium channel blockers + aspirin with patients on one or neither drug
Drug group
Number of people
Estimated median
P-value (log rank)
Multivariate cox regression
in group
survival (d)
compared to control
HR (95%CI)
P-value
Control (no CCB/aspirin)
98
601
-
1
-
CCB + aspirin
15
1414
0.029
0.332 (0.126-0.870)
0.025
Aspirin without CCB
40
392
0.032
1.658 (0.968-2.840)
0.066
CCB without Aspirin
11
343
0.563
1.039 (0.416-2.595)
0.935
Citation: Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242